Precigen, Inc. (PGEN) SEC Filings & Earnings Calls
EquiReason read 13 Precigen, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — First profitable quarter from continuing operations driven by $53.1M in Papzimeos sales, a major milestone..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 202610-QFirst profitable quarter from continuing operations driven by $53.1M in Papzimeos sales, a major milestone.earningsopen
Figures in the filing · each found in the filing text
| Product revenues · Papzimeos · Q2-2026 | $53M | |
| Net income (loss) · Q2-2026 | $20M | |
| Cash and cash equivalents · 2026-06-30 | $16M | |
| Investments · 2026-06-30 | $22M | |
| Operating cash flow · H1-2026 | $-62M | |
| Pre-launch inventory future estimated net revenues · Papzimeos · 2026-06-30 | $9M |
Guidance
Gross margins expected to stabilize between high 80% and low 90%
Management expects gross margins to stabilize at high levels, R&D to increase, and continued commercial ramp.
Risks flagged
Cash flow negative due to long payment terms
“Our customer payment terms on sales of Papzimeos are 127 days, driving the significant increase in accounts receivables.” · word for word
Dependence on single product for revenue
“Looking ahead, we expect that the majority of our future revenues for the foreseeable future will be derived from sales of Papzimeos as we continue to expand our commercial activities and market presence.” · word for word
Pre-launch inventory depletion may pressure gross margins
“As pre-launch inventory continues to absorb costs through the manufacturing process, we expect the current gross margins (exclusive of period costs expensed as incurred) will gradually decrease as pre-launch inventory is sold.” · word for word
4 Aug 20268-K · 2.02Total Revenue $55M (+6011% y/y); PAPZIMEOS Net Revenue $53M; Cash, Cash Equivalents, and Investments $39Mearningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q2-2026 | $55M | +6011% y/y |
| PAPZIMEOS Net Revenue · PAPZIMEOS · Q2-2026 | $53M | |
| Cash, Cash Equivalents, and Investments · Q2-2026 | $39M | |
| Patient Hub Enrollment · PAPZIMEOS · Q2-2026 | 500 | |
| Payer Coverage · PAPZIMEOS · Q2-2026 | 315,000,000 |
Risks flagged
Single product concentration risk
“PAPZIMEOS represents 96.5% of total revenue; any disruption would materially impact results”
Commercial execution risk for global expansion
“MAA under review by EMA; expansion into pediatric population planned”
Pipeline dependency on PRGN-2009
“PRGN-2009 Phase 2 trials ongoing; pipeline update expected by year-end”
24 Jun 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersopen
Risks flagged
Shareholder dilution risk from increased equity plan shares.
“7 million additional shares authorized for issuance under incentive plan.”
13 May 20268-K · 2.02PAPZIMEOS net product revenue $22M; Cash, cash equivalents, and investments $57M; Patients enrolled in hub 400earningsopen
Figures in the filing · each found in the filing text
| PAPZIMEOS net product revenue · PAPZIMEOS · Q1-2026 | $22M | |
| Cash, cash equivalents, and investments · Q1-2026 | $57M | |
| Patients enrolled in hub · PAPZIMEOS · Q1-2026 | 400 |
Risks flagged
Dependence on PAPZIMEOS commercial success; pipeline still early.
“Revenue solely from PAPZIMEOS; pipeline programs in earlier stages.”
Cash runway to break-even; execution risk.
“Cash expected to fund operations to cash flow break-even by end of 2026.”
13 May 202610-QProduct revenues $22M (+10650% y/y); Service revenues $1M (+25% y/y); Total revenues $23M (+1633% y/y); Guidance: Expects to finish selling pre-launch inventory in 2026; R&D to increaseopen
Figures in the filing · each found in the filing text
| Product revenues · Papzimeos · Q1-2026 | $22M | +10650% y/y |
| Service revenues · Exemplar · Q1-2026 | $1M | +25% y/y |
| Total revenues · Q1-2026 | $23M | +1633% y/y |
| Net loss · Q1-2026 | $-8M | -85% y/y |
| Research and development expenses · Q1-2026 | $6M | -46% y/y |
| Selling, general and administrative expenses · Q1-2026 | $21M | +70% y/y |
| Cash and cash equivalents · 2026-03-31 | $8M | |
| Investments · 2026-03-31 | $49M | |
| Operating cash flow · Q1-2026 | $-44M | +169% y/y |
Guidance
Expects to finish selling pre-launch inventory in 2026; R&D to increase
Management expects Papzimeos revenue to continue growing, gross margins to stabilize at high levels, and R&D to increase later in the year.
Risks flagged
Commercial execution risk
“Projected sales derived from pre-launch inventories depend on several factors that could materially impact actual realized results, including the timing and scale of product adoption within our target patient population, and payer coverage.” · word for word
Liquidity risk
“We have incurred losses since our inception, and as of March 31, 2026, we had an accumulated deficit of $2.3 billion.” · word for word
Dependence on single product
“Looking ahead, we expect that the majority of our future revenues will be derived from sales of Papzimeos” · word for word
30 Apr 2026DEF 14APrecigen filed its definitive proxy statement (DEF 14A) for the 2026 annual meeting, seeking shareholder approval to increase the 2023 Omnibus Incentive Plan share reserve by 7 million shares and to elect directors.open
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · FY2025 | $100M | |
| One-year shareholder return · FY2025 | 280.0% | |
| Registered patients (Papzimeos patient hub) · Papzimeos · FY2025 | 200 | |
| Target institutions engaged · Papzimeos · FY2025 | 90.0% | |
| Senior secured term loan facility · FY2025 | $125M | |
| CEO total compensation · FY2025 | $5M | |
| CEO bonus payout as percentage of target · FY2025 | 140.0% | |
| Net income (loss) · FY2025 | $-251M | |
| TSR (cumulative) · FY2025 | $40.98 | |
| Peer group TSR (cumulative) · FY2025 | $124.75 |
Risks flagged
Dependence on single product Papzimeos for near-term revenue
“The U.S. launch of Papzimeos is expected to drive significant revenue for Precigen in 2026 and beyond” · word for word
Significant net losses and negative cash flows
“Net Income (Loss) ($ Millions) (250.6)”
Concentrated ownership by Chairman Randal Kirk (35.9%)
“RJ Kirk and Affiliates ... Total Shares Beneficially Owned 133,956,416 ... Percentage of Shares Beneficially Owned 35.9%”
Potential dilution from equity incentive plan
“the number of shares remaining available for issuance under the 2026 Plan represented approximately 1.2% of our outstanding common stock” · word for word
31 Mar 2026SC 13D/AInsider Randal J. Kirk and affiliates sold 4.77M shares of Precigen, reducing beneficial ownership but remaining above 35%.open
Risks flagged
Insider selling reduces alignment
“The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221.” · word for word
31 Mar 2026SC 13D/AInsider Randal J. Kirk and affiliates sold 4.77M shares of Precigen, reducing beneficial ownership but remaining above 35%.open
Risks flagged
Insider selling reduces alignment
“The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221.” · word for word
25 Mar 20268-K · 2.02Net product revenue $3M; Cash, cash equivalents, and investments $100Mearningsopen
Figures in the filing · each found in the filing text
| Net product revenue · PAPZIMEOS · Q4-2025 | $3M | |
| Cash, cash equivalents, and investments · FY2025 | $100M |
Risks flagged
Commercial execution risk remains as launch is early-stage; payer adoption and patient uptake need to sustain.
“Launch momentum is strong but only one partial quarter of revenue; sustainability unproven.”
13 Nov 202510-QPGEN reported Q3 2025 results with total revenues up >200% but net loss widened significantly due to non-cash charges and increased SG&A expenses.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-146M | +510% y/y |
| Net loss per share attributable to common shareholders, basic and diluted · Q3-2025 | $-1.06 | +1078% y/y |
| Cash and cash equivalents · 2025-09-30 | $14M | |
| Investments · 2025-09-30 | $109M | |
| Net cash used in operating activities · 9M-2025 | $-64M | +7% y/y |
| Product revenues · Q3-2025 | $162000.00 | +146% y/y |
| Service revenues · Q3-2025 | $942000.00 | +6% y/y |
Risks flagged
Going concern risk
“We have incurred losses from continuing operations since our inception, and as of September 30, 2025, we had an accumulated deficit of $2.3 billion.” · word for word
Dilution risk
“To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common shareholders will be diluted” · word for word
Commercialization risk
“We currently have not generated any revenue from commercial product sales of Papzimeos.” · word for word
13 Nov 20258-K · 2.02Cash, cash equivalents and investments $124M; Patients registered in PAPZIMEOS Patient Hub 100; Lives covered by private insurance 100,000,000earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and investments · Q3-2025 | $124M | |
| Patients registered in PAPZIMEOS Patient Hub · Q3-2025 | 100 | |
| Lives covered by private insurance · Q3-2025 | 100,000,000 |
Risks flagged
Commercial execution risk; early launch stage
“Rapid commercial launch execution underway with full deployment of the sales team in September” · word for word
Dependence on single product PAPZIMEOS for revenue
“PAPZIMEOS is the first and only FDA-approved treatment for adults with RRP” · word for word
Precigen, Inc. — questions
- What did Precigen, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — First profitable quarter from continuing operations driven by $53.1M in Papzimeos sales, a major milestone.
Every figure on this page comes from Precigen, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.